communityacquir
pneumonia
cap
seriou
infecti
diseas
accompani
high
morbid
mortal
mortal
defin
common
infect
potenti
life
threaten
particularli
older
adult
along
comorbid
diseas
sever
cap
scap
gener
defin
cap
requir
admiss
intens
care
unit
due
invas
mechan
ventil
septic
shock
requir
vasopressor
relat
sever
mortal
approxim
patient
scap
may
die
short
time
report
onethird
patient
cap
requir
hospit
present
coinfect
bacteria
viru
streptococcu
pneumonia
pneumonia
influenza
main
bacteri
caus
cap
well
describ
pneumonia
act
signific
pathogen
age
group
virus
influenza
b
virus
parainfluenza
virus
well
adenovirus
also
consid
import
caus
cap
current
proper
antibiot
simpl
analges
accompani
adequ
rest
major
medic
pneumonia
macrolid
antibiot
demonstr
wide
appli
treat
cap
includ
pneumococc
pneumonia
due
excel
inhibit
pneumonia
atyp
organ
nevertheless
preval
influenza
virusassoci
pneumonia
role
bacteri
coinfect
prognosi
patient
poorli
describ
gener
popul
flexibl
bronchoscopi
combin
bronchoalveolar
lavag
bal
viabl
altern
sputum
acquisit
noninvas
sampl
unobtain
lower
respiratori
tract
pathogen
detect
bal
verifi
easi
molecul
biolog
method
use
improv
sensit
accuraci
diagnost
studi
patient
cap
nonrespons
empir
antibiot
therapi
howev
molecular
mechan
patholog
pathogen
remain
unclear
pneumonia
per
se
inflammatori
condit
caus
multipl
factor
report
pneumonia
strongli
associ
inflamm
caus
autophagi
apoptosi
mammalian
homolog
yeast
protein
sort
protein
suggest
play
vital
role
macroautophagi
vacuolar
protein
sort
meanwhil
necessari
develop
normal
mammalian
demonstr
play
pivot
role
pathogenesi
includ
cancer
phosphoryl
mediat
protein
kinas
b
akt
function
oncogenesi
autophagi
inhibit
meanwhil
phosphoinositid
akt
signal
pathway
mediat
pathogen
contribut
coordin
actin
rearrang
therebi
lead
intern
organ
studi
suggest
activ
target
rapamycin
mtor
signal
pathway
implic
lung
tumorigenesi
relat
highgrad
tumor
advanc
diseas
conclus
studi
carri
discuss
role
axi
reinfect
pneumonia
influenza
viru
april
decemb
patient
cap
male
femal
age
year
averag
age
year
qingdao
huangdao
district
central
hospit
collect
studi
includ
patient
met
criteria
cap
criteria
scap
infecti
diseas
societi
americaamerican
thorac
societi
guidelin
patient
exclud
studi
met
follow
criteria
patient
lung
neoplasm
noninfecti
pulmonari
interstiti
diseas
pulmonari
edema
atelectasi
pulmonari
embol
pulmonari
eosinophil
infiltr
pulmonari
vascul
patient
acquir
immun
defici
syndrom
human
immunodefici
viru
infect
patient
diagnos
tuberculosi
nontuberculosi
mycobacterium
infect
patient
admit
nurs
home
within
three
month
use
antibiot
within
three
month
consid
case
healthcareassoci
pneumonia
patient
show
lower
respiratori
tract
infect
h
admiss
consid
case
nosocomi
pneumonia
electrofiberopt
bronchoscopi
use
lavag
lung
segment
sublung
segment
select
patient
salin
water
ml
bronchoalveolar
lavag
fluid
balf
sputum
sampl
patient
cap
collect
detect
addit
balf
sampl
obtain
foreign
bodi
bronchu
healthi
control
collect
control
includ
nine
male
six
femal
whose
age
year
mean
age
year
microb
sputum
sampl
balf
solut
cultur
nest
polymeras
chain
reaction
pcr
conduct
detect
pneumonia
preliminari
vitro
studi
verifi
lower
limit
detect
colonyform
unitsml
specif
identifi
respiratori
disord
among
control
subject
studi
shown
primer
specif
detect
mani
pathogen
vitro
genom
dna
pneumonia
american
type
cultur
collect
atcc
use
posit
control
pcr
respiratori
virus
determin
multiplex
revers
transcript
pcr
assay
use
seeplex
ace
detect
kit
seegen
inc
seoul
korea
andor
shell
vial
cultur
strain
atcc
h
influenza
set
posit
control
total
rna
extract
use
trizol
invitrogen
carlsbad
ca
usa
integr
puriti
rna
determin
agaros
gel
electrophoresi
rt
reagent
rt
kit
takara
dalian
liaon
china
use
rt
target
gene
intern
refer
gene
glyceraldehyd
phosphat
dehydrogenas
gapdh
amplifi
fluoresc
qpcr
appli
biosystem
carlsbad
ca
usa
reaction
system
pcr
mrna
express
gene
calcul
method
primer
sequenc
shown
tabl
cell
lyse
radioimmunoprecipit
assay
ripa
lysat
contain
proteas
inhibitor
protein
concentr
determin
bicinchonin
acid
bca
assay
protein
sampl
bore
sodium
dodecyl
sulfat
polyacrylamid
gel
electrophoresi
electrotransf
polyvinyliden
fluorid
pvdf
membran
pvdf
membran
seal
skim
milk
powder
two
h
incub
primari
antibodi
overnight
primari
antibodi
includ
akt
pakt
mtor
pmtor
antibodi
purchas
abcam
inc
cambridg
usa
wash
trisbuff
salin
tbst
three
time
membran
incub
horseradish
peroxidas
hrp
label
goat
anti
rabbit
antibodi
immunoglobulin
g
igg
abcam
inc
cambridg
usa
one
h
final
membran
cover
diaminobenzidin
dab
solut
expos
enhanc
chemiluminesc
ecl
total
healthi
specif
pathogenfre
male
mice
eight
ten
week
weigh
g
purchas
better
bioengin
co
ltd
nanj
jiangsu
china
influenza
atcc
rockvil
md
allow
grow
cell
rivm
bilthoven
netherland
viru
harvest
repeat
freez
thaw
centrifug
min
tissu
cultur
infect
dose
viru
solut
calcul
titrat
cell
uninfect
cell
cultur
util
prepar
control
inocul
store
cell
contamin
respiratori
virus
includ
influenza
b
viru
human
parainfluenza
sendai
viru
respiratori
syncyti
viru
b
rhinoviru
enteroviru
coronaviru
adenoviru
exclus
contamin
determin
pcr
cell
cultur
viru
control
solut
dilut
phosphat
buffer
salin
pb
ph
primari
influenza
infect
secondari
pneumococc
pneumonia
induc
accord
previous
describ
method
mice
alloc
group
n
control
group
without
treatment
flu
group
infect
sp
group
inocul
pneumonia
flu
sp
group
inocul
pneumonia
infect
dimethyl
sulfoxid
dmso
flu
sp
group
inocul
pneumonia
infect
process
dmso
treatment
dmso
sp
group
inocul
pneumonia
process
dmso
treatment
inhibitor
sp
group
inocul
pneumonia
process
inhibitor
treatment
inhibitor
flu
sp
group
inocul
pneumonia
infect
process
inhibitor
treatment
oeneg
control
nc
sp
group
inocul
pneumonia
process
oenc
lentiviru
treatment
sp
group
inocul
pneumonia
process
lentiviru
treatment
oenc
flu
sp
group
inocul
pneumonia
infect
process
oenc
lentiviru
treatment
flu
sp
group
inocul
pneumonia
infect
process
lentiviru
treatment
oenc
lentiviru
vector
construct
shanghai
genepharma
co
ltd
shanghai
china
use
lentiviru
packag
cell
cell
cultur
medium
contain
fetal
bovin
serum
fb
subcultur
everi
day
first
two
week
inocul
viru
pneumonia
lentiviru
vector
introduc
lung
mice
nasal
inhal
two
time
week
total
four
week
trachea
expos
midlin
incis
intub
asept
abbocatht
cathet
abbott
sligo
ireland
bal
perform
inject
two
part
ml
asept
salin
right
lung
recov
balf
ml
rotat
min
precipit
resuspend
ml
steril
pb
total
number
cell
count
particl
counterand
size
analyz
beckmancoult
miami
fl
usa
differenti
cell
count
diffquick
baxter
uk
perform
cell
centrifug
smear
stain
modifi
giemsa
stain
accord
report
method
day
viru
infect
h
pneumococc
infect
ie
day
viru
infect
viral
load
determin
revers
transcript
quantit
pcr
rtqpcr
short
cdna
templat
deriv
cell
balf
use
realtim
qpcr
abi
prism
sequenc
detect
system
viral
load
sampl
calcul
use
standard
curv
particl
count
influenza
virus
viral
particl
count
electron
microscopi
primer
use
forward
revers
label
probe
h
pneumonia
infect
mice
anesthet
pentobarbit
sodium
sigmaaldrich
st
loui
mo
usa
balf
mice
group
obtain
recov
balf
ml
rotat
min
precipit
resuspend
ml
steril
pb
subsequ
suspens
dilut
time
final
diluent
ml
coat
sheep
blood
agar
plate
fix
colonyform
unit
count
h
later
tumor
necrosi
factor
tnf
interleukin
il
interferon
ifn
enzymelink
immunosorb
assay
elisa
kit
purchas
r
system
minneapoli
nm
usa
express
determin
balf
group
accord
instruct
kit
determin
myeloperoxidas
mpo
activ
perform
describ
earlier
bal
dilut
five
time
potassium
phosphat
buffer
ph
supplement
cetyltrimethylammonium
bromid
mm
ethylen
diamin
tetraacet
acid
activ
mpo
measur
oxid
benzidin
reaction
termin
ad
acet
acid
amount
transform
benzidin
determin
measur
optic
densiti
od
valu
nm
mpo
activ
express
unit
bal
liquidsml
unit
defin
amount
mpo
requir
produc
one
unit
per
minut
measur
mpo
activ
bal
solut
indic
activ
state
polymorphonuclear
cell
present
lung
lung
tissu
fix
formaldehyd
hydrat
gradient
alcohol
clear
xylen
slice
four
subsequ
tissu
dewax
xylen
hydrat
gradient
alcohol
stain
hematoxylin
min
differenti
alcohol
hydrochlor
acid
treat
ammonia
stain
eosin
three
min
afterward
tissu
hydrat
gradient
alcohol
clear
xylen
seal
neutral
balsam
observ
microscopi
lastli
imag
obtain
analyz
time
ordinari
optic
microscop
olympu
tokyo
japan
analysi
data
studi
perform
use
spss
statist
softwar
ibm
corp
armonk
ny
usa
measur
data
express
mean
standard
deviat
date
normal
distribut
analyz
student
test
two
group
oneway
analysi
varianc
anova
repeat
measur
anova
use
comparison
among
multipl
group
follow
dunnett
post
hoc
test
enumer
data
assess
use
chisquar
test
evalu
differ
among
group
surviv
curv
drawn
kaplanmei
differ
surviv
rate
scale
logrank
test
p
show
signific
differ
bacteri
pathogen
balf
collect
patient
cap
detect
result
show
compar
sputum
sampl
posit
rate
diseas
diagnosi
significantli
higher
use
balf
tabl
detect
respiratori
virus
clinic
sampl
balf
found
case
posit
sputum
sampl
case
posit
balf
sampl
p
tabl
result
suggest
balf
sampl
superior
tradit
sputum
sampl
detect
bacteri
pathogen
pneumonia
order
investig
whether
pathogenesi
reinfect
pneumonia
relat
signal
pathway
examin
express
relat
gene
alveolar
epitheli
cell
balf
viral
posit
patient
express
balf
significantli
lower
sputum
patient
reinfect
pneumonia
p
express
balf
viral
posit
patient
decreas
p
fig
five
case
randomli
select
group
determin
pathwayrel
protein
fig
c
suggest
contrast
normal
group
level
paktakt
pmtormtor
increas
protein
express
decreas
pne
flu
pne
group
p
rel
pne
group
level
paktakt
pmtormtor
increas
express
decreas
flu
pne
group
p
suggest
downregul
pathway
activ
reinfect
pneumonia
order
verifi
whether
signal
pathway
involv
influenza
viruss
pneumonia
reinfect
mice
relev
mous
model
establish
result
detect
surviv
rate
mice
group
suggest
infect
mice
die
control
group
flu
group
compar
control
group
flu
group
surviv
rate
mice
significantli
decreas
sp
group
decreas
flu
sp
group
p
fig
amount
viru
detect
lung
mice
show
number
influenza
virus
flu
flu
sp
group
increas
significantli
day
compar
day
fig
base
find
detect
popul
pneumonia
compar
day
number
pneumonia
sp
flu
sp
group
increas
significantli
day
p
detect
popul
pneumonia
flu
sp
group
significantli
higher
sp
group
p
fig
term
mpo
activ
measur
result
show
activ
mpo
sp
flu
sp
group
significantli
higher
control
group
p
fig
accord
result
observ
hematoxylin
eosin
stain
found
control
group
lung
tissu
mice
show
normal
state
howev
sp
group
inflammatori
cell
infiltr
alveolar
collaps
perivascular
peribronchiol
edema
found
lung
tissu
mice
lung
injuri
flu
sp
group
seriou
sp
group
fig
result
suggest
success
establish
mous
model
influenza
viruss
pneumonia
infect
investig
whether
signal
pathway
involv
diseas
process
examin
express
relat
gene
result
base
western
blot
analysi
indic
rel
control
group
level
paktakt
pmtormtor
significantli
increas
express
decreas
significantli
flu
sp
flu
sp
group
p
compar
flu
sp
group
level
paktakt
pmtormtor
flu
sp
group
increas
express
protein
decreas
p
fig
b
express
lung
tissu
group
mice
examin
immunohistochemistri
result
consist
western
blot
analysi
fig
result
suggest
signal
pathway
involv
process
influenza
viru
infect
express
inflammatori
factor
balf
group
detect
find
reveal
contrast
control
group
express
sp
flu
sp
group
significantli
increas
p
meanwhil
express
inflammatori
factor
flu
sp
group
significantli
higher
sp
group
p
fig
altogeth
suggest
signal
pathway
activ
cell
inflamm
aggrav
reinfect
pneumonia
influenza
viru
infect
mous
model
inhibitor
lentiviru
vector
use
nasal
caviti
inhal
evalu
express
relat
protein
lung
tissu
injuri
mice
result
rtqpcr
show
express
lung
tissu
mice
group
significantli
higher
oenc
group
p
fig
suggest
lentiviru
infect
effect
base
result
western
blot
analysi
show
level
paktakt
pmtormtor
inhibitor
sp
inhibitor
flu
sp
group
significantli
lower
dmso
sp
dmso
flu
sp
group
express
significantli
increas
p
fig
c
besid
pneumonia
bacteria
lung
tissu
mice
group
h
infect
detect
correspond
result
suggest
compar
dmso
flu
sp
group
bacteri
count
inhibitor
flu
sp
group
significantli
lower
dmso
flu
sp
group
p
rel
oenc
flu
sp
group
number
bacteria
lung
tissu
mice
flu
sp
group
decreas
significantli
p
fig
meanwhil
activ
mpo
measur
h
infect
comparison
dmso
sp
group
dmso
flu
sp
group
activ
mpo
inhibitor
sp
group
inhibitor
flu
sp
group
significantli
decreas
p
furthermor
contrast
oenc
sp
group
oenc
flu
sp
group
activ
mpo
lung
tissu
mice
sp
group
flu
sp
group
decreas
significantli
p
fig
patholog
chang
lung
tissu
mice
determin
stain
show
compar
dmso
sp
group
dmso
flu
sp
group
well
oenc
sp
group
oenc
flu
sp
group
degre
injuri
lung
tissu
mice
significantli
decreas
inhibitor
sp
group
inhibitor
flu
sp
group
well
sp
group
flu
sp
group
fig
consid
inflammatori
respons
found
express
decreas
lung
tissu
mice
inhibitor
sp
group
inhibitor
flu
sp
group
rel
dmso
sp
group
dmso
flu
sp
group
p
express
also
decreas
lung
tissu
mice
sp
group
flu
sp
group
comparison
oenc
sp
group
oenc
flu
sp
group
p
fig
result
suggest
inhibit
signal
pathway
overexpress
mous
model
inhibit
reinfect
pneumonia
influenza
viru
infect
thu
allevi
degre
injuri
gramposit
pathogen
pneumonia
regard
one
main
caus
agent
cap
incid
pneumococc
pneumonia
decreas
due
develop
widespread
applic
antibiot
pneumococc
vaccin
due
increas
resist
among
respiratori
pathogen
togeth
fact
pneumonia
consid
common
etiolog
agent
identifi
cap
strategi
antimicrobi
therapi
doubt
base
upon
caus
pathogen
local
resist
pattern
well
risk
factor
infect
resist
bacteria
howev
caus
agent
cap
routin
determin
china
especi
sever
case
present
studi
aim
discuss
molecular
mechan
reinfect
bacteria
plu
viru
figur
role
axi
reinfect
pneumonia
influenza
viru
collect
came
conclus
inhibit
signal
pathway
overexpress
favor
suppress
reinfect
pneumonia
influenza
viru
infect
scap
first
studi
demonstr
balf
sampl
superior
tradit
sputum
sampl
detect
bacteri
pathogen
pneumonia
bal
use
steril
fluid
wash
pathogen
directli
bal
wide
applic
adult
children
determin
reason
ventilatorassoci
pneumonia
nosocomi
pneumonia
sever
cap
recalcitr
pneumonia
addit
balf
suggest
easili
suitabl
multipl
detect
method
microscopi
aerob
cultur
pcr
well
viral
cultur
bal
noninvas
method
henc
safe
patient
previou
studi
suggest
bal
could
use
tool
identif
pathogen
ventilatorassoci
pneumonia
acut
hypoxem
respiratori
failur
requir
noninvas
ventil
anoth
literatur
also
elucid
util
bal
act
less
invas
option
assess
lung
patholog
could
also
aid
diagnosi
cytomegaloviru
pneumon
use
molecular
method
therefor
bal
accur
safe
method
valid
pathogen
pneumonia
addit
present
studi
also
demonstr
express
downregul
pathway
activ
reinfect
pneumonia
besid
pneumonia
similar
studi
studi
reveal
express
markedli
downregul
cartilag
tissu
osteoarthr
report
compon
complex
also
target
kinas
akt
sever
studi
elucid
activ
happen
host
cell
invas
process
streptococcu
agalactia
agalactia
involv
detect
invas
process
agalactia
togeth
human
pathogen
suggest
respons
inflamm
occur
recent
studi
suggest
activ
akt
great
import
engulf
p
aeruginosa
extracellular
pathogen
loss
bacteri
motil
result
correspond
loss
stimul
phagocytosi
akt
taken
togeth
signal
pathway
collabor
regul
pneumonia
progress
furthermor
studi
also
indic
inhibit
pathway
overexpress
inhibit
pneumonia
symptom
pathogen
infect
regul
autophagi
initi
interact
complex
regul
vacuolar
protein
sort
cytokinesi
well
receptor
degrad
regul
complex
ii
demonstr
ectop
express
suppress
cancer
cell
prolifer
vitro
tumorigen
potenti
vivo
therebi
impli
role
autophagi
tumor
suppress
pathway
signal
transduct
pathway
implic
regul
great
deal
cellular
function
cell
prolifer
differenti
adhes
invas
report
signal
pathway
frequent
initi
regul
transmembran
receptor
signal
follow
activ
src
kinas
recruit
activ
kierbal
et
al
observ
blockad
cellular
activ
abl
prevent
p
aeruginosa
entri
kidney
hela
epitheli
cell
therefor
promis
target
pneumonia
treatment
conclus
novel
aforement
find
assert
may
open
novel
chapter
futur
scap
treatment
studi
demonstr
bal
accur
method
clinic
diagnosi
pneumonia
signal
pathway
inhibit
capabl
suppress
reinfect
pneumonia
influenza
viru
infect
scap
fig
howev
potenti
mechan
underli
role
signal
pathway
requir
investig
futur
follow
studi
